Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02452892 · ClinicalTrials.gov registry record · NA
Low Field Magnetic Stimulation (LFMS) in Subjects With Treatment-Resistant Depression (TRD)
A NA study of Depression and Depressive Disorder, Major, sponsored by Tal Medical.
- Completed
- Registry status
- NA
- Development phase
- 122
- Enrollment target
- 12
- Study locations
NCT02452892: Completed NA study of Depression and Depressive Disorder, Major, sponsored by Tal Medical.
NCT02452892 is a NA study of Depression and Depressive Disorder, Major that has completed, run by Tal Medical. The registered enrollment target is 122 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (84% lower). The trial reports 12 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02452892, a NA study of Depression and Depressive Disorder, Major, has completed, sponsored by Tal Medical.
- COMPLETED
- Registry status
- NA
- Development phase
- 122 participants
- Enrollment target
- 12
- Study locations
Study Summary
The purpose of this study is to compare the relative effectiveness of 20 and 60 minutes of Low-Field Magnetic Stimulation in relieving symptoms in patients with major depression who are treatment resistant.
Primary Outcome
Hamilton Rating Scales for Depression were designed to measure the severity of depressive symptoms in subjects with primary depressive illness. HAM-D6 is a subset of the HAM-D17 that assesses 6 items associated with major depression. The scale uses HAM-D17 items 1, 2, 7, 8, 10 and 13. Item 13 is scored 0 to 2 and all others are scored 0 to 4. Total score ranges from 0 to 22; higher score indicates more depression. Change from baseline: mean score at Week 1 Day 4 minus mean score at baseline". W
Conditions Studied
Interventions
- DEVICE LFMS
Study Locations (12)
California
- CNS Trials - Garden Grove
- Synergy Escondido - Lemon Grove
- Pacific Trials Partners - Oakland
Florida
- Sarkis Clinical Trials - Gainesville
- CNS Healthcare - Jacksonville
- Segal Institute - Lauderhill
Georgia
- Institute for Advanced Medical Research - Alpharetta
- Radiant Research - Atlanta
Ohio
- Neurobehavioral-Clinical Research - Canton
- Midwest Clinical - Dayton
Texas
- Future Search Trials - Dallas
Washington
- Northwest Clinical Research Center - Bellevue
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 122 participants |
| Start Date | 2015-09 |
| Est. Completion | 2016-10 |
| Phase | NA |
What the finished NCT02452892 record still lists
NCT02452892 is an interventional study that assigns participants to a tested intervention. The registered 122 participants enrollment target is mid-sized for trials with a published cap, below the 786-participant average among 679 other Depression trials with a reported enrollment target (84% lower).
The record links to 4 conditions, with Depression appearing as the primary indexed condition, and to 1 intervention - of which LFMS is the first listed.
NCT02452892 lists 12 locations in 6 states (California, Florida, Georgia).
Frequently Asked Questions
What is clinical trial NCT02452892 about?
NCT02452892 is a clinical study titled "Low Field Magnetic Stimulation (LFMS) in Subjects With Treatment-Resistant Depression (TRD)". The purpose of this study is to compare the relative effectiveness of 20 and 60 minutes of Low-Field Magnetic Stimulation in relieving symptoms in patients with major depression who are treatment resistant.
What is the current status of trial NCT02452892?
This trial is currently completed. It is a NA study. The enrollment target is 122 participants. The study started on 2015-09. Estimated completion is 2016-10.
What conditions does trial NCT02452892 study?
This clinical trial studies the following conditions: Depression, Depressive Disorder, Major, Depressive Disorder, Depressive Disorder, Treatment-Resistant.
What interventions are being tested in trial NCT02452892?
The interventions under investigation include: LFMS (DEVICE).
Who is sponsoring clinical trial NCT02452892?
This trial is sponsored by Tal Medical, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02452892 being conducted?
This trial has 12 study locations across California, Florida, Georgia, Ohio, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02452892's enrollment target sits among peer trials
122 290th of 679 higher than 390 of 679 other Depression trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Depression trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Reaching Out to Distressed Medical Residents, Fellows and Faculty
RECRUITING · NA
-
IMPACT (IMproving Proactive Approaches for Cancer Survivors' Mental Health Treatment)
RECRUITING · NA
-
Cold and Heat Investigation to Lower Levels of Depression
RECRUITING · NA
-
Dosing rTMS for Depression Post-SCI
RECRUITING · NA
-
Exploring Virtual Reality Adventure Training Exergaming
RECRUITING · NA
-
Brief Interventions for Coping with Distress
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03363373 · 122 participants · Phase 2
Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow
- NCT03463954 · 122 participants · NA
Confirmatory Clinical Evaluation of Novilase® Laser Therapy for Focal Destruction of Malignant Breast Tumors
- NCT04503265 · 122 participants · Phase 1
A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
- NCT04700527 · 122 participants · Phase 1
The Effects of SCFA Supplementation in Subjects Receiving Abdominopelvic RT: A Randomized Controlled Study
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia